Article Sidebar
Views PDF: 340
IMMUNOGENICITY OF RUBELLA VACCINE OF MEASLES AND RUBELLA COMBINED VACCINE (MRVAC) MANUFACTERING BY POLYVAC
Main Article Content
Abstract
Objectives: To assess immunogenicity of rubella vaccine of MRVAC vaccine. Subjects and method: Randomized, controlled and single-blind clinical trial study was conducted on 756 people aged 1 to 45 years old in Ha Nam and Hoa Binh provinces, measured rubella antibody titre by EIA technique, analysed indexes to evaluate immunogenicity. Results and conclusion: in negative antibody group, post-vaccination seroconversion rate was from 98.4% to 99.3%, MRVAC post-vaccination geometric mean titre (GMT) was 32.00 EIA unit, significantly lower than control vaccine. In possitiveantibody group, MRVAC post-vaccination GMT was 49.87 EIA units, equivalent to pre-vaccination and control vaccine.
Article Details
Keywords
MRVAC vaccine; Immunogenicity; Rubella vaccine
References
2. Trần Như Dương, Vũ Hải Hà, Phạm Quang Thái và cs (2016), "Một số đặc điểm dịch tễ hội chứng rubella bẩm sinh được giám sát tại Bệnh viện Nhi Trung ương, 2011-2016", Tạp chí Y học dự phòng, 10(183): 35-42.
3. Takeuchi Y, Togashi T, Sunakawa K et al (2002), "Field trial of combined measles and rubella live attenuated vaccine", Infectious disease magazine, 76(1), pp.56-62.
4. WHO (2008), The Immunological Basis for Immunization Series. Module 11: Rubella 2008.
5. Susan E. Reef, Stanley A. Plotkin (2017), "Rubella Vaccines", Plotkin's Vaccines,7th edition, Elsevier, Philadelphia, USA: 970-1000.